phlda2 Search Results


gene exp phlda2 mm00493899 g1  (Thermo Fisher)
85
Thermo Fisher gene exp phlda2 mm00493899 g1
Gene Exp Phlda2 Mm00493899 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp phlda2 mm00493899 g1/product/Thermo Fisher
Average 85 stars, based on 1 article reviews
gene exp phlda2 mm00493899 g1 - by Bioz Stars, 2026-04
85/100 stars
  Buy from Supplier
gene exp phlda2 hs00169368 m1  (Thermo Fisher)
87
Thermo Fisher gene exp phlda2 hs00169368 m1
Gene Exp Phlda2 Hs00169368 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 87/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp phlda2 hs00169368 m1/product/Thermo Fisher
Average 87 stars, based on 1 article reviews
gene exp phlda2 hs00169368 m1 - by Bioz Stars, 2026-04
87/100 stars
  Buy from Supplier
phlda2  (OriGene)
91
OriGene phlda2
The relative expression of pleckstrin homology domain family A (PHLDA) genes in normal and lung adenocarcinoma (LUAD) tissues according to The Cancer Genome Atlas (TCGA) datasets and the relative expression of PHLDA genes in normal and malignant mesothelioma (MM) tissues according to GSE51024 raw data. (A) PHLDA1, (B) <t>PHLDA2,</t> and (C) PHLDA3 in LUAD subtype tissue, (D) PHLDA1, (E) PHLDA2, and (F) PHLDA3 in MM tissue. (A) All PHLDA genes were highly expressed in LUAD when compared to normal tissue. (D) PHLDA1 gene expression in MM was lower than in normal tissue; (F) PHLDA3 gene expression was significantly higher than in normal tissue; (E) no statistical difference was found for PHLDA2 expression between MM and normal samples.
Phlda2, supplied by OriGene, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phlda2/product/OriGene
Average 91 stars, based on 1 article reviews
phlda2 - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
antibodies against phlda2  (Proteintech)
93
Proteintech antibodies against phlda2
Validation of <t>PHLDA2</t> expression in HCC. ( A ) Expression levels of PHLDA2 in HCC tissues and adjacent tissues by IHC. ( B ) Immunohistochemical analysis of PHLDA2 expression in 58 pairs of HCC tissues and adjacent tissues. ( C ) Western Blot analysis of PHLDA2 expression in 6 pairs of HCC tissues and adjacent tissues.
Antibodies Against Phlda2, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against phlda2/product/Proteintech
Average 93 stars, based on 1 article reviews
antibodies against phlda2 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier
gene exp phlda2 bt03249477 g1  (Thermo Fisher)
86
Thermo Fisher gene exp phlda2 bt03249477 g1
Validation of <t>PHLDA2</t> expression in HCC. ( A ) Expression levels of PHLDA2 in HCC tissues and adjacent tissues by IHC. ( B ) Immunohistochemical analysis of PHLDA2 expression in 58 pairs of HCC tissues and adjacent tissues. ( C ) Western Blot analysis of PHLDA2 expression in 6 pairs of HCC tissues and adjacent tissues.
Gene Exp Phlda2 Bt03249477 G1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp phlda2 bt03249477 g1/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
gene exp phlda2 bt03249477 g1 - by Bioz Stars, 2026-04
86/100 stars
  Buy from Supplier
gene exp tbp hs00427621 m1  (Thermo Fisher)
99
Thermo Fisher gene exp tbp hs00427621 m1
Validation of <t>PHLDA2</t> expression in HCC. ( A ) Expression levels of PHLDA2 in HCC tissues and adjacent tissues by IHC. ( B ) Immunohistochemical analysis of PHLDA2 expression in 58 pairs of HCC tissues and adjacent tissues. ( C ) Western Blot analysis of PHLDA2 expression in 6 pairs of HCC tissues and adjacent tissues.
Gene Exp Tbp Hs00427621 M1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/gene exp tbp hs00427621 m1/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
gene exp tbp hs00427621 m1 - by Bioz Stars, 2026-04
99/100 stars
  Buy from Supplier
placental phlda2 expression  (Janssen)
90
Janssen placental phlda2 expression
Validation of <t>PHLDA2</t> expression in HCC. ( A ) Expression levels of PHLDA2 in HCC tissues and adjacent tissues by IHC. ( B ) Immunohistochemical analysis of PHLDA2 expression in 58 pairs of HCC tissues and adjacent tissues. ( C ) Western Blot analysis of PHLDA2 expression in 6 pairs of HCC tissues and adjacent tissues.
Placental Phlda2 Expression, supplied by Janssen, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/placental phlda2 expression/product/Janssen
Average 90 stars, based on 1 article reviews
placental phlda2 expression - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
phlda2 +/+bacx1(129) studs  (Envigo)
90
Envigo phlda2 +/+bacx1(129) studs
Experimental paradigm. (A) Experimental groups. WT = Wildtype offspring with normal expression (X1) of <t>Phlda2</t> born from a wildtype mating. Tg = Transgenic offspring with overexpression (X2) of Phlda2 born from mating wildtype females to transgenic studs. These animals have a reduced placental endocrine compartment, exhibit restricted fetal growth ( ) and are also exposed to an adverse maternal environment ( ). NTg = Non-transgenic offspring with normal expression (X1) of Phlda2 born from mating wildtype females to transgenic studs, which are exposed to adverse maternal environment ( ). (B) Timeline detailing the behavioural test batteries of the three cohorts. Cohort 1: DSI = direct social interaction test, L/D = light/dark box test, SP = social propinquity test, SOD = social olfactory discrimination test, ERT = exploratory reluctance test, and 3CT = three-chamber test. Cohort 2: CC = classical conditioning task, 5CSRTT = five-choice serial reaction time task, CT = consumption test, Activity = locomotor activity, OF = open field test and FCM = fecal cortisol metabolite measure. Cohort 3: LCA = lick cluster analysis and Activity = locomotor activity.
Phlda2 +/+Bacx1(129) Studs, supplied by Envigo, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phlda2 +/+bacx1(129) studs/product/Envigo
Average 90 stars, based on 1 article reviews
phlda2 +/+bacx1(129) studs - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
monoclonal antibody raised against a partial recombinant human phlda2 h00007262-m01  (Abnova)
90
Abnova monoclonal antibody raised against a partial recombinant human phlda2 h00007262-m01
Experimental paradigm. (A) Experimental groups. WT = Wildtype offspring with normal expression (X1) of <t>Phlda2</t> born from a wildtype mating. Tg = Transgenic offspring with overexpression (X2) of Phlda2 born from mating wildtype females to transgenic studs. These animals have a reduced placental endocrine compartment, exhibit restricted fetal growth ( ) and are also exposed to an adverse maternal environment ( ). NTg = Non-transgenic offspring with normal expression (X1) of Phlda2 born from mating wildtype females to transgenic studs, which are exposed to adverse maternal environment ( ). (B) Timeline detailing the behavioural test batteries of the three cohorts. Cohort 1: DSI = direct social interaction test, L/D = light/dark box test, SP = social propinquity test, SOD = social olfactory discrimination test, ERT = exploratory reluctance test, and 3CT = three-chamber test. Cohort 2: CC = classical conditioning task, 5CSRTT = five-choice serial reaction time task, CT = consumption test, Activity = locomotor activity, OF = open field test and FCM = fecal cortisol metabolite measure. Cohort 3: LCA = lick cluster analysis and Activity = locomotor activity.
Monoclonal Antibody Raised Against A Partial Recombinant Human Phlda2 H00007262 M01, supplied by Abnova, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal antibody raised against a partial recombinant human phlda2 h00007262-m01/product/Abnova
Average 90 stars, based on 1 article reviews
monoclonal antibody raised against a partial recombinant human phlda2 h00007262-m01 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
flexi halotag cdna clone of phlda2  (Kazusa Genome Technologies)
90
Kazusa Genome Technologies flexi halotag cdna clone of phlda2
Candidate target genes regulated by miR‐148a‐5p
Flexi Halotag Cdna Clone Of Phlda2, supplied by Kazusa Genome Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/flexi halotag cdna clone of phlda2/product/Kazusa Genome Technologies
Average 90 stars, based on 1 article reviews
flexi halotag cdna clone of phlda2 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
anti-phlda2 a6244  (ABclonal Biotechnology)
90
ABclonal Biotechnology anti-phlda2 a6244
Candidate target genes regulated by miR‐148a‐5p
Anti Phlda2 A6244, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-phlda2 a6244/product/ABclonal Biotechnology
Average 90 stars, based on 1 article reviews
anti-phlda2 a6244 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

Image Search Results


The relative expression of pleckstrin homology domain family A (PHLDA) genes in normal and lung adenocarcinoma (LUAD) tissues according to The Cancer Genome Atlas (TCGA) datasets and the relative expression of PHLDA genes in normal and malignant mesothelioma (MM) tissues according to GSE51024 raw data. (A) PHLDA1, (B) PHLDA2, and (C) PHLDA3 in LUAD subtype tissue, (D) PHLDA1, (E) PHLDA2, and (F) PHLDA3 in MM tissue. (A) All PHLDA genes were highly expressed in LUAD when compared to normal tissue. (D) PHLDA1 gene expression in MM was lower than in normal tissue; (F) PHLDA3 gene expression was significantly higher than in normal tissue; (E) no statistical difference was found for PHLDA2 expression between MM and normal samples.

Journal: Journal of Thoracic Disease

Article Title: The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma

doi: 10.21037/jtd-20-2909

Figure Lengend Snippet: The relative expression of pleckstrin homology domain family A (PHLDA) genes in normal and lung adenocarcinoma (LUAD) tissues according to The Cancer Genome Atlas (TCGA) datasets and the relative expression of PHLDA genes in normal and malignant mesothelioma (MM) tissues according to GSE51024 raw data. (A) PHLDA1, (B) PHLDA2, and (C) PHLDA3 in LUAD subtype tissue, (D) PHLDA1, (E) PHLDA2, and (F) PHLDA3 in MM tissue. (A) All PHLDA genes were highly expressed in LUAD when compared to normal tissue. (D) PHLDA1 gene expression in MM was lower than in normal tissue; (F) PHLDA3 gene expression was significantly higher than in normal tissue; (E) no statistical difference was found for PHLDA2 expression between MM and normal samples.

Article Snippet: The staining was performed with antibodies against PHLDA1 (sc6142, clone M-20, dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, EUA; RRID:AB_2163292), PHLDA2 (polyclonal antibody, CAT#: TA344404, dilution 1:50; Origene, OriGene Technologies, Rockville, USA), PHLDA3 (polyclonal antibody, CAT#: TA315261, dilution 1:100; Origene, OriGene Technologies, Rockville, USA) and tumor suppressor P53 (clone 318-6-11, dilution 1:200; DAKO, Via Real Carpinteria, CA, USA).

Techniques: Expressing

Clinicopathological characteristics of the patients with lung cancer from TCGA database (Chi-square test; P value <0.05)

Journal: Journal of Thoracic Disease

Article Title: The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma

doi: 10.21037/jtd-20-2909

Figure Lengend Snippet: Clinicopathological characteristics of the patients with lung cancer from TCGA database (Chi-square test; P value <0.05)

Article Snippet: The staining was performed with antibodies against PHLDA1 (sc6142, clone M-20, dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, EUA; RRID:AB_2163292), PHLDA2 (polyclonal antibody, CAT#: TA344404, dilution 1:50; Origene, OriGene Technologies, Rockville, USA), PHLDA3 (polyclonal antibody, CAT#: TA315261, dilution 1:100; Origene, OriGene Technologies, Rockville, USA) and tumor suppressor P53 (clone 318-6-11, dilution 1:200; DAKO, Via Real Carpinteria, CA, USA).

Techniques: Translocation Assay, Mutagenesis, Expressing

Clinicopathological characteristics of the patients with malignant mesothelioma from TCGA database (Chi-square test; P value <0.05)

Journal: Journal of Thoracic Disease

Article Title: The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma

doi: 10.21037/jtd-20-2909

Figure Lengend Snippet: Clinicopathological characteristics of the patients with malignant mesothelioma from TCGA database (Chi-square test; P value <0.05)

Article Snippet: The staining was performed with antibodies against PHLDA1 (sc6142, clone M-20, dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, EUA; RRID:AB_2163292), PHLDA2 (polyclonal antibody, CAT#: TA344404, dilution 1:50; Origene, OriGene Technologies, Rockville, USA), PHLDA3 (polyclonal antibody, CAT#: TA315261, dilution 1:100; Origene, OriGene Technologies, Rockville, USA) and tumor suppressor P53 (clone 318-6-11, dilution 1:200; DAKO, Via Real Carpinteria, CA, USA).

Techniques:

This Kaplan Meier survival curve shows the correlation between pleckstrin homology domain family A (PHLDA) genes expression and overall survival (OS), first progression survival (FPS) and post progression survival (PPS) in lung cancer patients. (A) Low expression of the PHLDA1 gene was correlated with worse OS (HR =0.77, 95% CI: 0.63–0.94; P<0.01); (B) high expression of the PHLDA2 gene was significantly associated with better OS (HR =0.84, 95% CI: 0.74–0.96; P<0.01); (C) high expression of the PHLDA3 gene also correlated with worse OS (HR =1.25, 95% CI: 1.1–1.42; P<0.01); (D) low expression of the PHLDA1 gene showed a significant correlation with worse FPS (HR =0.66, 95% CI: 0.47–0.93; P=0.02); (E) PHLDA2 gene expression was not statistically significant on FPS (HR =1.14, 95% CI: 0.92–1.40; P=0.24); (F) high expression of the PHLDA3 gene was significantly correlated with worse FPS (HR =1.78, 95% CI: 1.41–2.24; P<0.01); (G) low expression of the PHLDA1 gene showed a significant correlation with worse PPS (HR =0.43, 95% CI: 0.26–0.72; P<0.01); (H) PHLDA2 gene expression was not statistically significant on PPS (HR =0.82, 95% CI: 0.62–1.08; P=0.16); (I) high expression of the PHLDA3 gene was significantly correlated with worse PPS (HR =1.37, 95% CI: 1.02–1.83; P=0.03).

Journal: Journal of Thoracic Disease

Article Title: The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma

doi: 10.21037/jtd-20-2909

Figure Lengend Snippet: This Kaplan Meier survival curve shows the correlation between pleckstrin homology domain family A (PHLDA) genes expression and overall survival (OS), first progression survival (FPS) and post progression survival (PPS) in lung cancer patients. (A) Low expression of the PHLDA1 gene was correlated with worse OS (HR =0.77, 95% CI: 0.63–0.94; P<0.01); (B) high expression of the PHLDA2 gene was significantly associated with better OS (HR =0.84, 95% CI: 0.74–0.96; P<0.01); (C) high expression of the PHLDA3 gene also correlated with worse OS (HR =1.25, 95% CI: 1.1–1.42; P<0.01); (D) low expression of the PHLDA1 gene showed a significant correlation with worse FPS (HR =0.66, 95% CI: 0.47–0.93; P=0.02); (E) PHLDA2 gene expression was not statistically significant on FPS (HR =1.14, 95% CI: 0.92–1.40; P=0.24); (F) high expression of the PHLDA3 gene was significantly correlated with worse FPS (HR =1.78, 95% CI: 1.41–2.24; P<0.01); (G) low expression of the PHLDA1 gene showed a significant correlation with worse PPS (HR =0.43, 95% CI: 0.26–0.72; P<0.01); (H) PHLDA2 gene expression was not statistically significant on PPS (HR =0.82, 95% CI: 0.62–1.08; P=0.16); (I) high expression of the PHLDA3 gene was significantly correlated with worse PPS (HR =1.37, 95% CI: 1.02–1.83; P=0.03).

Article Snippet: The staining was performed with antibodies against PHLDA1 (sc6142, clone M-20, dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, EUA; RRID:AB_2163292), PHLDA2 (polyclonal antibody, CAT#: TA344404, dilution 1:50; Origene, OriGene Technologies, Rockville, USA), PHLDA3 (polyclonal antibody, CAT#: TA315261, dilution 1:100; Origene, OriGene Technologies, Rockville, USA) and tumor suppressor P53 (clone 318-6-11, dilution 1:200; DAKO, Via Real Carpinteria, CA, USA).

Techniques: Expressing

This Kaplan Meier survival curve shows the correlation between pleckstrin homology domain family A (PHLDA) genes expression and overall survival (OS) in malignant mesothelioma patients according to the The Cancer Genome Atlas (TCGA) Firehose Legacy datasets. (A) High expression of the PHLDA1 (HR=1.80, 95% CI: 1.1–2.9; P=0.01) and (B) PHLDA2 (HR=1.87, 95% CI: 1.2–3.0; P<0.01) genes was significant correlated with worse OS; (C) PHLDA3 gene expression was not correlated with survival (HR =1.29, 95% CI: 0.8–2.1; P=0.27).

Journal: Journal of Thoracic Disease

Article Title: The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma

doi: 10.21037/jtd-20-2909

Figure Lengend Snippet: This Kaplan Meier survival curve shows the correlation between pleckstrin homology domain family A (PHLDA) genes expression and overall survival (OS) in malignant mesothelioma patients according to the The Cancer Genome Atlas (TCGA) Firehose Legacy datasets. (A) High expression of the PHLDA1 (HR=1.80, 95% CI: 1.1–2.9; P=0.01) and (B) PHLDA2 (HR=1.87, 95% CI: 1.2–3.0; P<0.01) genes was significant correlated with worse OS; (C) PHLDA3 gene expression was not correlated with survival (HR =1.29, 95% CI: 0.8–2.1; P=0.27).

Article Snippet: The staining was performed with antibodies against PHLDA1 (sc6142, clone M-20, dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, EUA; RRID:AB_2163292), PHLDA2 (polyclonal antibody, CAT#: TA344404, dilution 1:50; Origene, OriGene Technologies, Rockville, USA), PHLDA3 (polyclonal antibody, CAT#: TA315261, dilution 1:100; Origene, OriGene Technologies, Rockville, USA) and tumor suppressor P53 (clone 318-6-11, dilution 1:200; DAKO, Via Real Carpinteria, CA, USA).

Techniques: Expressing

The PHLDA-drug interaction network obtained from the Comparative Toxicogenomics Database. (A) PHLDA1-drug interaction network; (B) PHLDA2-drug interaction network; (C) PHLDA3-drug interaction network. This network shows that several common drugs could potentially modulate the mRNA or protein expression of PHLDA. PHLDA, pleckstrin homology domain family A.

Journal: Journal of Thoracic Disease

Article Title: The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma

doi: 10.21037/jtd-20-2909

Figure Lengend Snippet: The PHLDA-drug interaction network obtained from the Comparative Toxicogenomics Database. (A) PHLDA1-drug interaction network; (B) PHLDA2-drug interaction network; (C) PHLDA3-drug interaction network. This network shows that several common drugs could potentially modulate the mRNA or protein expression of PHLDA. PHLDA, pleckstrin homology domain family A.

Article Snippet: The staining was performed with antibodies against PHLDA1 (sc6142, clone M-20, dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, EUA; RRID:AB_2163292), PHLDA2 (polyclonal antibody, CAT#: TA344404, dilution 1:50; Origene, OriGene Technologies, Rockville, USA), PHLDA3 (polyclonal antibody, CAT#: TA315261, dilution 1:100; Origene, OriGene Technologies, Rockville, USA) and tumor suppressor P53 (clone 318-6-11, dilution 1:200; DAKO, Via Real Carpinteria, CA, USA).

Techniques: Expressing

Cluster analysis of the PPI network. (A) PHLDA1-PPI network. (B) PHLDA2-PPI network, and (C) PHLDA3-PPI network. PHLDA, pleckstrin homology domain family A; PPI, protein-protein interaction.

Journal: Journal of Thoracic Disease

Article Title: The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma

doi: 10.21037/jtd-20-2909

Figure Lengend Snippet: Cluster analysis of the PPI network. (A) PHLDA1-PPI network. (B) PHLDA2-PPI network, and (C) PHLDA3-PPI network. PHLDA, pleckstrin homology domain family A; PPI, protein-protein interaction.

Article Snippet: The staining was performed with antibodies against PHLDA1 (sc6142, clone M-20, dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, EUA; RRID:AB_2163292), PHLDA2 (polyclonal antibody, CAT#: TA344404, dilution 1:50; Origene, OriGene Technologies, Rockville, USA), PHLDA3 (polyclonal antibody, CAT#: TA315261, dilution 1:100; Origene, OriGene Technologies, Rockville, USA) and tumor suppressor P53 (clone 318-6-11, dilution 1:200; DAKO, Via Real Carpinteria, CA, USA).

Techniques:

PHLDA protein expression using immunohistochemistry on tissue microarrays (TMAs) in MM and LUAD. H&E staining of an epithelioid MM section/showing blocks of epithelioid cells infiltrating sparse desmoplasic stroma (A); H&E staining of a representative solid subtype LUAD composed of cohesive and poor differentiated malignant cells, aggregated in blocks and immersed in exuberant desmoplasic stroma (B). Immunohistochemistry: PHLDA1 staining of mild number of epithelioid MM cells (arrows, C) and LUAD cells (arrows, D); PHLDA2 with strong and diffuse cytoplasmic staining with perinuclear accentuation in numerous MM malignant cells (arrows, E), contrasting with diffuse cytoplasmic staining in a mild number of LUAD malignant cells (arrows, F); PHLDA3 with diffuse cytoplasmic expression in MM malignant cells (arrows, G), and cytoplasmic staining with perinuclear accentuation in a mild number of LUAD malignant cells (arrows, H); strong and diffuse P53 nuclear staining in LUAD (arrows, J) and weak, almost absent, in MM (I). PHLDA, pleckstrin homology domain family A; H&E, hematoxylin & eosin; LUAD, lung adenocarcinoma; MM, malignant mesothelioma.

Journal: Journal of Thoracic Disease

Article Title: The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma

doi: 10.21037/jtd-20-2909

Figure Lengend Snippet: PHLDA protein expression using immunohistochemistry on tissue microarrays (TMAs) in MM and LUAD. H&E staining of an epithelioid MM section/showing blocks of epithelioid cells infiltrating sparse desmoplasic stroma (A); H&E staining of a representative solid subtype LUAD composed of cohesive and poor differentiated malignant cells, aggregated in blocks and immersed in exuberant desmoplasic stroma (B). Immunohistochemistry: PHLDA1 staining of mild number of epithelioid MM cells (arrows, C) and LUAD cells (arrows, D); PHLDA2 with strong and diffuse cytoplasmic staining with perinuclear accentuation in numerous MM malignant cells (arrows, E), contrasting with diffuse cytoplasmic staining in a mild number of LUAD malignant cells (arrows, F); PHLDA3 with diffuse cytoplasmic expression in MM malignant cells (arrows, G), and cytoplasmic staining with perinuclear accentuation in a mild number of LUAD malignant cells (arrows, H); strong and diffuse P53 nuclear staining in LUAD (arrows, J) and weak, almost absent, in MM (I). PHLDA, pleckstrin homology domain family A; H&E, hematoxylin & eosin; LUAD, lung adenocarcinoma; MM, malignant mesothelioma.

Article Snippet: The staining was performed with antibodies against PHLDA1 (sc6142, clone M-20, dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, EUA; RRID:AB_2163292), PHLDA2 (polyclonal antibody, CAT#: TA344404, dilution 1:50; Origene, OriGene Technologies, Rockville, USA), PHLDA3 (polyclonal antibody, CAT#: TA315261, dilution 1:100; Origene, OriGene Technologies, Rockville, USA) and tumor suppressor P53 (clone 318-6-11, dilution 1:200; DAKO, Via Real Carpinteria, CA, USA).

Techniques: Expressing, Immunohistochemistry, Staining

Median densities of PHLDAs and TP53 according to histological type (N=102) (Mann-Whitney test; P value <0.05)

Journal: Journal of Thoracic Disease

Article Title: The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma

doi: 10.21037/jtd-20-2909

Figure Lengend Snippet: Median densities of PHLDAs and TP53 according to histological type (N=102) (Mann-Whitney test; P value <0.05)

Article Snippet: The staining was performed with antibodies against PHLDA1 (sc6142, clone M-20, dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, EUA; RRID:AB_2163292), PHLDA2 (polyclonal antibody, CAT#: TA344404, dilution 1:50; Origene, OriGene Technologies, Rockville, USA), PHLDA3 (polyclonal antibody, CAT#: TA315261, dilution 1:100; Origene, OriGene Technologies, Rockville, USA) and tumor suppressor P53 (clone 318-6-11, dilution 1:200; DAKO, Via Real Carpinteria, CA, USA).

Techniques:

PHLDA and p53 protein expression and clinicopathologic characteristics of the patients with lung cancer and malignant mesothelioma (Chi-square test; P value <0.05)

Journal: Journal of Thoracic Disease

Article Title: The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma

doi: 10.21037/jtd-20-2909

Figure Lengend Snippet: PHLDA and p53 protein expression and clinicopathologic characteristics of the patients with lung cancer and malignant mesothelioma (Chi-square test; P value <0.05)

Article Snippet: The staining was performed with antibodies against PHLDA1 (sc6142, clone M-20, dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, EUA; RRID:AB_2163292), PHLDA2 (polyclonal antibody, CAT#: TA344404, dilution 1:50; Origene, OriGene Technologies, Rockville, USA), PHLDA3 (polyclonal antibody, CAT#: TA315261, dilution 1:100; Origene, OriGene Technologies, Rockville, USA) and tumor suppressor P53 (clone 318-6-11, dilution 1:200; DAKO, Via Real Carpinteria, CA, USA).

Techniques: Expressing

The univariate and multivariate analysis employed a Cox proportional hazards model

Journal: Journal of Thoracic Disease

Article Title: The expression patterns and prognostic significance of pleckstrin homology-like domain family A (PHLDA) in lung cancer and malignant mesothelioma

doi: 10.21037/jtd-20-2909

Figure Lengend Snippet: The univariate and multivariate analysis employed a Cox proportional hazards model

Article Snippet: The staining was performed with antibodies against PHLDA1 (sc6142, clone M-20, dilution 1:100; Santa Cruz Biotechnology, Santa Cruz, CA, EUA; RRID:AB_2163292), PHLDA2 (polyclonal antibody, CAT#: TA344404, dilution 1:50; Origene, OriGene Technologies, Rockville, USA), PHLDA3 (polyclonal antibody, CAT#: TA315261, dilution 1:100; Origene, OriGene Technologies, Rockville, USA) and tumor suppressor P53 (clone 318-6-11, dilution 1:200; DAKO, Via Real Carpinteria, CA, USA).

Techniques:

Validation of PHLDA2 expression in HCC. ( A ) Expression levels of PHLDA2 in HCC tissues and adjacent tissues by IHC. ( B ) Immunohistochemical analysis of PHLDA2 expression in 58 pairs of HCC tissues and adjacent tissues. ( C ) Western Blot analysis of PHLDA2 expression in 6 pairs of HCC tissues and adjacent tissues.

Journal: Scientific Reports

Article Title: Characteristics of lactate metabolism phenotype in hepatocellular carcinoma

doi: 10.1038/s41598-023-47065-0

Figure Lengend Snippet: Validation of PHLDA2 expression in HCC. ( A ) Expression levels of PHLDA2 in HCC tissues and adjacent tissues by IHC. ( B ) Immunohistochemical analysis of PHLDA2 expression in 58 pairs of HCC tissues and adjacent tissues. ( C ) Western Blot analysis of PHLDA2 expression in 6 pairs of HCC tissues and adjacent tissues.

Article Snippet: IHC was conducted using antibodies against PHLDA2 from Proteintech Group Inc. (14661-1-AP, 1:1000, Chicago, USA).

Techniques: Biomarker Discovery, Expressing, Immunohistochemical staining, Western Blot

Experimental paradigm. (A) Experimental groups. WT = Wildtype offspring with normal expression (X1) of Phlda2 born from a wildtype mating. Tg = Transgenic offspring with overexpression (X2) of Phlda2 born from mating wildtype females to transgenic studs. These animals have a reduced placental endocrine compartment, exhibit restricted fetal growth ( ) and are also exposed to an adverse maternal environment ( ). NTg = Non-transgenic offspring with normal expression (X1) of Phlda2 born from mating wildtype females to transgenic studs, which are exposed to adverse maternal environment ( ). (B) Timeline detailing the behavioural test batteries of the three cohorts. Cohort 1: DSI = direct social interaction test, L/D = light/dark box test, SP = social propinquity test, SOD = social olfactory discrimination test, ERT = exploratory reluctance test, and 3CT = three-chamber test. Cohort 2: CC = classical conditioning task, 5CSRTT = five-choice serial reaction time task, CT = consumption test, Activity = locomotor activity, OF = open field test and FCM = fecal cortisol metabolite measure. Cohort 3: LCA = lick cluster analysis and Activity = locomotor activity.

Journal: Human Molecular Genetics

Article Title: Placental endocrine insufficiency programs anxiety, deficits in cognition and atypical social behaviour in offspring

doi: 10.1093/hmg/ddab154

Figure Lengend Snippet: Experimental paradigm. (A) Experimental groups. WT = Wildtype offspring with normal expression (X1) of Phlda2 born from a wildtype mating. Tg = Transgenic offspring with overexpression (X2) of Phlda2 born from mating wildtype females to transgenic studs. These animals have a reduced placental endocrine compartment, exhibit restricted fetal growth ( ) and are also exposed to an adverse maternal environment ( ). NTg = Non-transgenic offspring with normal expression (X1) of Phlda2 born from mating wildtype females to transgenic studs, which are exposed to adverse maternal environment ( ). (B) Timeline detailing the behavioural test batteries of the three cohorts. Cohort 1: DSI = direct social interaction test, L/D = light/dark box test, SP = social propinquity test, SOD = social olfactory discrimination test, ERT = exploratory reluctance test, and 3CT = three-chamber test. Cohort 2: CC = classical conditioning task, 5CSRTT = five-choice serial reaction time task, CT = consumption test, Activity = locomotor activity, OF = open field test and FCM = fecal cortisol metabolite measure. Cohort 3: LCA = lick cluster analysis and Activity = locomotor activity.

Article Snippet: Test subjects were obtained from breeding virgin 129S2/SvHsd (129) females (Envigo, UK) with Phlda2 +/+BACx1(129) ( ) studs to generate Phlda2 +/+BACx1(129) transgenic (Tg) and Phlda2 +/+ non-transgenic (NTg) experimental animals, respectively.

Techniques: Expressing, Transgenic Assay, Over Expression, Activity Assay

Candidate target genes regulated by miR‐148a‐5p

Journal: Cancer Science

Article Title: Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre‐ miR‐148a on gene regulation

doi: 10.1111/cas.13610

Figure Lengend Snippet: Candidate target genes regulated by miR‐148a‐5p

Article Snippet: A Flexi HaloTag cDNA clone of PHLDA2 (Vector: pFN21A, Product ID: FHC02241) was purchased from Kazusa Genome Technologies (Chiba, Japan).

Techniques: Expressing

Downregulated genes by si‐PHLDA2 transfectants

Journal: Cancer Science

Article Title: Molecular pathogenesis of pancreatic ductal adenocarcinoma: Impact of passenger strand of pre‐ miR‐148a on gene regulation

doi: 10.1111/cas.13610

Figure Lengend Snippet: Downregulated genes by si‐PHLDA2 transfectants

Article Snippet: A Flexi HaloTag cDNA clone of PHLDA2 (Vector: pFN21A, Product ID: FHC02241) was purchased from Kazusa Genome Technologies (Chiba, Japan).

Techniques: Binding Assay